BACKGROUND: Men diagnosed with localized prostate cancer seek information on how treatment options may impact their healthrelated quality of life (HRQOL). The authors used latent profile analysis (LPA) to group men according to their symptom burden and functional status and to identify patient characteristics associated with each HRQOL profile. METHODS: Patients completed the Patient-Reported Outcomes Measurement Information System and the Expanded Prostate Index Composite measures 3 months after treatment initiation. Anxiety, depression, fatigue, sleep disturbance, pain, diarrhea, urinary obstruction, urinary incontinence, erectile function, and sex satisfaction were modeled jointly using LPA, and the analysis was adjusted for covariates to examine associations between patient characteristics and profiles. RESULTS: One-third of the 373 men were not non-Hispanic white (26% were black). Four LPA profiles were identified. Men who experienced the "best HRQOL" were less likely to receive treatment, to be older, and to smoke. Men in the second best profile experienced symptoms similar to men in the best HRQOL group but reported poor sexual and urinary function, because they were more likely to receive therapy. The third profile included men with increased symptom burden and poor functioning who were likely to undergo prostatectomy and to have increased comorbidity. The "worst HRQOL" group experienced the worst symptoms and the poorest functioning, and these men were more likely to be younger, to have more comorbidities, and to smoke. CONCLUSIONS: LPA revealed that men who receive the same treatment can experience very different HRQOL impact. Understanding the factors most associated with poorer HRQOL allows clinicians to focus their care on individuals most in need of symptom management and support. Cancer 2018;124:2832-40. V C 2018 American Cancer Society.
INTRODUCTION
Prostate cancer is the most frequently diagnosed cancer and the third-leading cause of death from cancer among men in the United States. 1 Although men who receive treatment for prostate cancer often experience excellent long-term survival, treatments can have severe impacts on men's lives. For example, prostatectomy is associated with decreased sexual and urinary functioning. 2 Radiation is associated with increased bowel-related problems. 2 Given the high survival rates for men with this disease, it is important to identify ways to improve health-related quality of life (HRQOL) for patients with prostate cancer.
The short-term risks and impacts of each treatment modality have different patterns in men with localized prostate cancer. Through research, it is critical to understand which types of men are more likely to experience specific decrements in physical, mental, and social well being. By identifying at-risk men, clinicians can proactively develop and implement tailored HRQOL interventions and management strategies that will support their HRQOL needs, [3] [4] [5] [6] [7] [8] which can help to set patient expectations more accurately regarding potential HRQOL outcomes after treatment and aid with decisions about treatment selection. 7, [9] [10] [11] [12] To do this, it is important to consider the multidimensional aspects of HRQOL. HRQOL studies either summarize HRQOL as a single score (ie, global HRQOL) by aggregating items across multiple domains or use multiple scores to represent different domains of HRQOL (eg, physical function, sexual function, urinary function, bowel function). With a single global HRQOL score, we can identify men whose lives are impacted more or less by exposure to the cancer treatment but are unable to understand the specific aspects of HRQOL (eg, physical, psychological, functional, social) that are most impacted and thus could benefit from targeted support. Modeling each HRQOL domain score individually is more informative for cancer care but does not take into account the patterns of HRQOL impact jointly.
For the current study, we used latent profile analysis (LPA) to simultaneously model each HRQOL domain and identify subgroups of men who experienced similar symptom and functional impacts. LPA groups men who have similar HRQOL patterns together into a subgroup or "latent profile." We examined HRQOL in men with localized prostate cancer 3 months after treatment initiation, a time point at which HRQOL is most negatively impacted by treatment. [13] [14] [15] [16] We hypothesized that profiles would be primarily driven by prostate cancer treatment modality (eg, prostatectomy, radiation, hormone therapy, no treatment). Therefore, we expected a subgroup of men that would report both sexual and urinary problems (more associated with surgery) and another subgroup that would report bowel problems (associated with radiation). Our analyses also included general HRQOL symptom and functioning domains, such as fatigue, pain, depression, anxiety, sleep disturbance, and physical functioning. Once HRQOL profiles were identified, we examined sociodemographic and clinical factors that are routinely collected in clinic to identify men who were at increased risk for having poorer HRQOL profiles.
MATERIALS AND METHODS

Participants
The North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS) is a population-based, prospective, observational, comparativeeffectiveness research study examining the impact of localized prostate cancer on the lives of men. 17 By using rapid case ascertainment through the North Carolina Central Cancer Registry, men with newly diagnosed prostate cancer were recruited from all 100 counties in North Carolina. Treating physicians of identified men were given a 2-week period to opt their patients out of the study. Subsequently, a letter and brochure were mailed to each patient describing the study. To participate, men had to speak English and receive their cancer care in North Carolina. Of 2473 eligible men, 1419 (57%) enrolled in the study from January 2011 to June 2013. Participants completed surveys by telephone at baseline (before receiving treatment) and 3 months after treatment initiation. Participants who did not receive treatment completed surveys at 6 months after diagnosis. Additional details on NC ProCESS are described elsewhere. 17 In September 2012, we received additional funding from the National Cancer Institute to include measures from the Patient-Reported Outcomes Measurement Information System (PROMIS) in the original study. Because PROMIS measures were added approximately 21 months after the NC ProCESS began enrolling patients, smaller numbers of participants completed PROMIS measures at baseline (n 5 333) and at the 3-month survey (n 5 411) than in the parent study. The analytic data set for this study at the 3-month survey was 373 men, because 12 men did not complete the relevant patient-reported outcome measures, and 26 received nonstandard treatment. Men who receive nonstandard treatment, including cryotherapy and high-intensity focused ultrasound, can experience distinctly different side-effect profiles, and the numbers of these patients were too few for meaningful inclusion in our analysis. This study was approved by the University of North Carolina Institutional Review Board.
Data and Measures
Participants self-reported sociodemographic characteristics and comorbid conditions. Sociodemographic characteristics included age at diagnosis, race, ethnicity, education (eighth grade or less, some high school, high school diploma/General Educational Development test, some college, college graduate or more), marital status, employment status, insurance status (no/other, Medicaid/ Medicare, private), and smoking status (never, former, current). Comorbid conditions included Alzheimer disease (dementia), arthritis, back pain, asthma, chronic obstructive pulmonary disease, diabetes, human immunodeficiency virus, kidney disease, osteoporosis, anemia, rheumatic disease, liver, cancer (other than prostate), pancreatitis, inflammatory bowel disease, stomach ulcer, depression, anxiety, high blood pressure, congestive heart failure, chest pain, heart attack, arrhythmia, peripheral artery disease, blood clots, high cholesterol, and stroke. From these comorbid conditions, we created an indicator representing the number of comorbid conditions that men reported as limiting their daily activities.
Treatment types included prostatectomy, radiation therapy (external beam and/or brachytherapy), radiation therapy with hormone therapy, and no treatment as of 3 months after treatment initiation, as abstracted from medical records. In addition, we abstracted Gleason scores (range, 0-10) as a measure of disease severity and created 3 Gleason score categories: 6, 7, 8.
HRQOL was assessed with the National Institutes of Health PROMIS measures and the Expanded Prostate Index Composite (EPIC) measure. PROMIS measures included anxiety, depression, fatigue, pain interference, sleep disturbance, diarrhea, erectile function, sexual satisfaction, and physical function. PROMIS measures have undergone rigorous evaluation, including validation in men with prostate cancer. [18] [19] [20] [21] PROMIS scores are normed to the US general population at a mean of 50 and a standard deviation of 10. Higher symptom scores reflect increased symptom burden, and higher function scores reflect better functioning. The EPIC includes measures of urinary incontinence and urinary obstruction. 22 Higher scores on the EPIC indicate worse urinary functioning. The EPIC function scores were rescaled to have a mean of 50 and a standard deviation of 10 to present them sideby-side with PROMIS scores.
Analysis
We used a K-means approach 23 to identify HRQOL profiles. This approach divides participants according to the 11 HRQOL measures into k clusters based on the distances between participants and the cluster means, assigning each observation to the closest cluster. In general, Euclidian distance (ie, the sum of squares of the component differences) is used; and, under the Euclidian distance, Kmeans can be viewed as a special case (ie, most parsimony) of an LPA model, in that it not only assumes local independence but also assumes equal variances for all manifest variables. All 11 HRQOL measures were normed to have a standard deviation of 10, and this validates the equal variances assumption underlying the K-means approach and is 1 of the key motivations in our choice of this parsimonious model. To view K-means as a special LPA model brings 1 change to the classic K-means approach: we could obtain posterior profile membership probabilities for each participant. We used both content knowledge and statistical evidence (Bayesian information criteria [BIC], with higher BIC indicating better balance between fitness and model parsimony) to select the appropriate number of profiles. For the selected latent profile model, we calculated entropy 24, 25 as a coarse measure of uncertainty in posterior classification.
Once we decided on the final latent profile model, we examined whether patient-level characteristics, as described above, were associated with profile membership. We developed a method to conduct K-means analysis with covariates based on the R package mclust 26, 27 and completed the analyses in 2 steps. First, for each covariate, we conducted a K-means analysis with this single covariate and used the likelihood-ratio test to evaluate whether this covariate was significantly associated with profile membership. We used a P value threshold of .10 to screen candidate covariates. The second step in our analyses was an adjusted K-means analysis in which we included all patient-level covariates that passed the screening from step 1. We simplified this model by excluding covariates that did not exhibit a statistically significant association with class membership after adjusting for other covariates. For the final adjusted K-means analysis, we calculated adjusted odds ratios and 95% confidence intervals for all estimates in the second-step analyses.
RESULTS
Sociodemographic and clinical characteristics for the 373 men are presented in Table 1 . One-third of the sample represented racial/ethnic minority groups, and 32% had less than a high school education. At the 3-month survey, 38% of men had undergone prostatectomy, 22% had received radiation therapy, 3% had received radiation and hormone therapy, and 37% had not received any treatment.
The 4-profile solution provided better fit (BIC, 228,751) and interpretable solution than the 2-profile (BIC, 228,992), 3-profile (BIC, 228,847), and 5-profile (BIC, 228,733) models. The 5-profile solution resulted in a very small group that was difficult to interpret. Entropy for the 4-profile model was 0.825, indicating clear delineation of profiles. Figure 1 provides details of the 4 profiles across symptoms and functional status.
At the screening step of examining potential covariates that might be associated with profile membership, age, treatment, race, employment, Gleason score, comorbidities, education, smoking status, marital status, and insurance type passed the screening (P threshold of .10) and thus were entered in the multivariable analysis. The first multivariable analysis with all selected covariates revealed that race, Gleason score, and marital status were no longer significant (P > .10) after controlling for other patient covariates. Therefore, only age, treatment, employment, comorbidities that impact daily activities, education, smoking status, and insurance type were included in the final model. Table 1 provides details of the distribution of sociodemographic and clinical characteristics associated with each profile. Table 2 provides the unadjusted means on the symptoms and functional status for each of the 4 profiles (as illustrated in Fig. 1 ). Table 3 presents adjusted odds ratios from the multivariable model for patient characteristics associated with profile membership relative to the men who experienced the best HRQOL. In a sensitivity analysis, we repeated the LPA but removed the 11 men who received hormone and radiation therapy and observed no differences from the primary model findings. Therefore, we decided to include these 11 participants to increase the generalizability of results.
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Latent profile 1 was the "best HRQOL" profile and included men with the lowest symptom burden and highest functional status. The best HRQOL profile was used as the reference group for all comparisons featured in Table 3 and included 34% of the men. Men in this profile were more likely not to receive treatment compared with all other profiles and were more likely not to have any comorbidities that limited their daily activities compared with men in latent profiles 3 and 4. In addition, men in the best HRQOL profile were more likely to be older than men in profile 4 and more likely not to smoke compared with men in profiles 3 and 4. Latent profile 2 was considered "good HRQOL with some urinary incontinence and poor sexual functioning," reflecting 33% of men who had relatively similar symptoms and physical functioning as the men in the "best HRQOL" group but experienced urinary incontinence and obstruction symptoms, poor erectile function, and low satisfaction with sex. Compared with men in latent profile 1, those in profile 2 were more likely to undergo prostatectomy or receive radiation therapy than no treatment, less likely to receive a combination of radiation and hormone therapy, and less likely to have private insurance coverage. They were similar in age to men in the "best HRQOL" group.
Men in latent profile 3 had "elevated symptoms with some urinary incontinence and erectile dysfunction and poor functioning." Twenty-six percent of men in the sample were in profile 3. Compared with men who had the best HRQOL profile, men in the elevated symptom profile were more likely to undergo prostatectomy and to report greater comorbidity burden.
Finally, latent profile 4 was considered the "worst HRQOL" profile, representing approximately 7% of men in the sample. Compared with men in the best HRQOL group, men in in the worst HRQOL group were younger, had more comorbidities that limited daily activities, were more likely to be employed part time than full time, and were more likely to be smokers.
DISCUSSION
By using a variation of LPA, a novel methodology, we identified 4 distinct HRQOL profiles among men with localized prostate cancer 3 months after they initiated treatment. LPA is a more patient-centered approach for examining groups of men differentially impacted in terms of symptom burden and functional status within a single statistical model. Therefore, we are able to identify specific patient-level characteristics associated with membership in 4 latent profiles. Although treatment type was associated with profile membership, there was no HRQOL profile that included 1 treatment type. For example, men who underwent prostatectomy experienced urinary symptoms and sexual dysfunction, but they ended up in separate profiles. In the second best HRQOL profile (profile 2), the men experienced no additional symptoms. However other men who underwent prostatectomy did Approximately 33% of men experienced the best HRQOL and were less likely to receive treatment 6 months after diagnosis, were older, had less comorbidities, and were nonsmokers. Seven percent of men were in the poorest HRQOL group. Although this is a relatively small percentage, we are not concerned with the stability of the profile, because: 1) the profile had a distinct pattern in terms of symptom burden and functional status, and 2) the median posterior membership probabilities for men in the profile was .988 (range, .565-1.000), indicating a very clear separation from other profiles. In multivariable models, men in the poorest HRQOL group were more likely to be younger, to have greater comorbidity burden, and to be smokers. In univariable models, these men were more likely to be black and to have lower levels of education, less likely to be employed full time, less likely to be married or partnered, and more likely to have no insurance or public insurance than men who reported the best HRQOL.
Identifying men who are most susceptible to membership in poor HRQOL profiles would be of great interest to oncologists. [10] [11] [12] 28 That is, men at greatest risk for having a poor HRQOL profile could be flagged early in their prostate cancer care to anticipate their specific HRQOL and symptom needs. These patients may benefit especially from close monitoring of HRQOL and management and could be identified for future clinical trials that test interventions to improve their HRQOL. Greater comorbidity burden also was strongly associated with membership in the 2 poorest HRQOL profiles. This finding highlights the importance of care coordination for complex patients with cancer. All participants in the poorest HRQOL profile and 99% of those in the second poorest HRQOL profile reported at least 1 physical health comorbidity. Many men also reported mental health comorbidities in addition to comorbidities that limited their usual or daily activities. Because the average age of diagnosis for men with prostate cancer is 66 years, it is not surprising that many men also have other health conditions. 29, 30 However, the burden that these additional health conditions place on prostate-related functional status and symptom burden must be addressed. If complex patients who have multiple comorbid conditions could be better supported beginning from the time of prostate cancer diagnosis, we might realize considerable improvements in their HRQOL and functional status. Previous studies have demonstrated that better HRQOL can lead to better medication adherence and even to better survival. [31] [32] [33] Previous work has documented that black and white individuals unevenly share the burden of cancer. [34] [35] [36] In the current study, we observed an over-representation of black men in the 2 poorest HRQOL profiles (52% white men and 44% black men were in the poorest profile; 62% white men and 36% black men were in the second poorest profile; and 75% white men and 21% black men were in the best HRQOL profile). In the univariable models, racial differences were statistically significant. When patient-level factors that may mediate the relations between race and HRQOL (such as comorbidities, insurance, and employment status) were added to the model, race was no longer statistically significant. However, compared with white men in the study, black men had a significantly higher comorbidity burden (P 5 .018) and were more likely to be current smokers (P 5 .0001) and less likely to have private insurance coverage (P 5 .001). These mediators appear to partially explain the racial disparities we observe between black men and white men in the unadjusted models. This observation underscores the importance of using patient-level factors to identify patients who may be at greater risk for membership in the poorest HRQOL profiles. Given the relation between race and low socioeconomic status, in addition to greater comorbidity burden and poor health behaviors (ie, smoking), black men may face additional challenges that negatively impact their HRQOL after prostate cancer treatment. Targeting HRQOL early in the cancer care continuum offers opportunities not only for improved HRQOL but also potentially to reduce racial disparities in HRQOL.
Our findings are consistent with previous studies that applied similar methods for subgroup analyses of HRQOL in patients with cancer. One study of 84 men with prostate cancer who received radiation therapy also identified 4 HRQOL subgroups or profiles. 37 From best to poorest HRQOL 8 weeks after starting therapy, the profiles were labeled as "resilient," "adjusted," "emerging," and "distressed." Similar to our study, younger men were more likely to be in the distressed profile. In another study of 402 men with prostate cancer who received cancer treatment, 5 symptom clusters 8 months after diagnosis were identified. 38 Approximately 50% of men were in the best HRQOL cluster, whereas the other clusters were associated with spikes in certain symptoms, such as pain and fatigue (cluster 1), urinary and sexual problems (cluster 2), fatigue and emotional distress (cluster 3), and bowel problems (cluster 4). Men across all 5 subgroups experienced some degree of other symptoms. Finally, a study of 168 patients with a variety of cancers (49% had prostate cancer) observed 3 HRQOL profiles. 39 Similar to our current study, membership in the poorest HRQOL profile was significantly associated with young age and more comorbid conditions. This is consistent with the HRQOL cancer literature, which has reported that younger adults may report greater susceptibility to HRQOL decrements than older adults. This could be related to expectations (eg, erectile dysfunction, family obligations, returning to work) that may be of somewhat less concern among older men who are often retired, may already have experienced declined in sexual function, and do not have young children at home.
Our study has some limitations. First, the men included in the study resided in North Carolina, and it is unclear whether the results can be generalized to men in other states. In addition, this was a cross-sectional study examining functional status and symptoms 3 months after treatment initiation. Future studies will build on this work by exploring HRQOL trends over time. Another limitation of this work is that we aggregated comorbidities into overall counts. Future work should consider individual conditions (eg, arthritis) and their distinct impacts on HRQOL. The number of profiles was selected using a combination of the BIC fit index and model interpretability. We acknowledge that some studies discuss limitations of the BIC for selecting the number of latent profiles for finite mixture models, but there is a lack of consensus on the "best" fit criteria to use. The current study focused more on profile interpretability, although this relied on Original Article guidance from BIC values. In addition, we implemented the K-means approach to drive the clustering, which corresponded to a mixture of multivariate normal model (latent profile model) with a very simple correlation structure. We also considered models with more complicated covariance structures but ultimately determined that the K-means approach generated more interpretable profiles. The correlation structure among the HRQOL items (ie, symptom burdens and functional status) would be too complicated to be captured by a prespecified covariance structure. Therefore, we selected the simple, but robust, K-means approach as the optimal covariance model choice.
Overall, we observed that the identified HRQOL profiles were associated with treatment but were not exclusively driven by treatment modality. That is, treatments were distributed across HRQOL profiles, and the strongest predictors of poor HRQOL profile membership were an individual's comorbidity burden, age, and health behaviors. It appears that combined sociodemographic and clinical characteristics work synergistically to negatively impact functioning and symptoms for men with prostate cancer.
Together, these findings inform greater understanding and patient-centered decision making for clinicians and for men diagnosed with localized prostate cancer. Thus, as patients select particular treatment modalities, they will be have a better understanding of potential symptoms, functional impacts, and the likelihood that they may end up with a better or worse HRQOL profile. Therefore, the additional data will inform their decisions, which will be based on their values and preferences. 10, 40 Clinicians will gain a better understanding of who may end up with a worse HRQOL profile and will be able to provide tailored symptom management. These findings emphasize a more holistic, patient-centered approach to treating patients that focuses on both treatment-related side effects (eg, bowel, urinary, sexual functioning) and other key HRQOL domains (eg, depression, anxiety, sleep disturbance).
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